Loading clinical trials...
Loading clinical trials...
Real-word Assessment of the Clinical Characteristics and Adherence to the European Society of Cardiology Guideline-Directed Medical Therapies in Heart Failure Care Management in France: REMOTE-HF Study.
The goal of this observational study was to evaluate trends and determinants of SGLT2 inhibitor (SGLT2i) prescriptions in heart failure patients from 2021 to 2024, particularly in relation to LVEF subgroups and evolving scientific evidence (EMPEROR-Preserved, DELIVER, 2023 Guidelines). Participant population were adults with heart failure using the Satelia®Cardio web application to remotely monitor their condition. The main questions it aims to answer are: * to compare the prescription of treatments (including doses, and distribution of patients according to various therapeutic classes recommend for heart failure) with ESC recommendations to see to what extent GDMTs are adhered to. * to quantify the association between the presence of treatments and the risk of alerts/hospitalizations and overall death and as a function of LVEF using telemonitoring. * to evaluate the adherence across patient profiles and cardiologist practices (outpatient vs. hospital-based). Participants will complete follow-up, quality-of-life and patient support questionnaires and provide data regarding their treatments on the web application.
A retrospective, multicenter descriptive study was conducted in France from January 1, 2021 to December 31, 2024. The REMOTE-HF study included 17,551 patients enrolled in remote monitoring program for heart failure (HF) management. We described and analyzed the implementation of ESC guidelines in patients monitored remotely with a web application named Satelia®Cardio (NP Medical). Key clinical parameters such as age, gender, NYHA class, LVEF, and HF etiology were analyzed. Prescribed therapies including ACEi/ARB/ARNis, beta-blockers, MRAs, and SGLT2 inhibitors, were compared against the European Society of Cardiology (ESC) guideline-directed medical therapies (GDMTs). Adherence was evaluated across patient profiles and cardiologist practices (outpatient vs. hospital-based) in France.
Age
18 - 105 years
Sex
ALL
Healthy Volunteers
No
Medical Affairs Department, NP Medical
Bordeaux, France
Start Date
January 1, 2021
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
June 15, 2025
17,551
ACTUAL participants
Lead Sponsor
Sophie NISSE-DURGEAT
NCT07484009
NCT07191730
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions